Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE), previously known as ChromaDex Corp., has revealed encouraging results from a clinical study involving individuals with Werner Syndrome (WS), a rare genetic condition characterized by accelerated aging. The study, published in Aging Cell, was led by researchers at Chiba University in Japan. The company, currently valued at over $1 billion, has shown remarkable market performance with a 144% year-to-date return. According to InvestingPro analysis, the company maintains strong financial health with a current ratio of 3.66, indicating solid liquidity management.
The double-blind, placebo-controlled trial lasted 52 weeks and included a crossover design, allowing participants to switch between the Niagen supplement and a placebo. Nine individuals with an average age of 47 were administered 1,000 mg/day of Niagen, resulting in a significant elevation of blood NAD+ levels by approximately 140%. In contrast, the placebo group experienced a 4% decrease.
Key improvements were observed in cardiovascular and skin health markers. Niagen supplementation led to a notable reduction in arterial stiffness, as measured by the cardio-ankle vascular index (CAVI), and an increase in large HDL particles, which are associated with cardiovascular benefits. The study also found that Niagen aided in wound healing by reducing skin ulcer size and heel pad thinning, while ulcers worsened in the placebo group.
No moderate or severe adverse events were reported throughout the study, and mild events were less frequent in the Niagen group compared to the placebo group. Although mild liver enzyme elevations were observed, they were manageable and consistent with Werner Syndrome’s characteristic liver sensitivities.
This research contributes to a growing body of evidence supporting the therapeutic potential of NAD+ augmentation with Niagen in rare, age-related diseases. Niagen has previously been granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Ataxia Telangiectasia (AT), highlighting its potential value in rare disease populations. The company’s strong market position is reflected in its impressive 29.77% revenue growth over the last twelve months. For a comprehensive analysis of NAGE’s market position and growth potential, investors can access detailed research through InvestingPro, which offers exclusive insights and 18 additional ProTips for this stock.
The findings from this study support further investigation into NAD+ augmentation as a therapeutic strategy for rare progeroid diseases, which share characteristics with common age-related conditions. The information provided is based on a press release statement from Niagen Bioscience.
In other recent news, Niagen Bioscience Inc. reported a robust first quarter of 2025, with net sales reaching $30.5 million, a 38% increase compared to the same period last year. The company also turned around its financial performance, reporting a net income of $5.1 million, up from a net loss of $500,000 in Q1 2024. This growth was driven by strong performances in both e-commerce sales and the Niagen ingredient business, which saw a 31% and 95% year-over-year increase, respectively. Analysts had forecasted revenue of $27.07 million, but Niagen exceeded expectations with actual sales of $30.5 million. Additionally, Niagen Bioscience has raised its full-year top-line growth outlook to 20-25%, reflecting confidence in its ongoing expansion efforts. The company is also planning to target 1,000 clinics for its NIAGEN plus product by the end of 2025 and is developing an at-home injectable version expected in Q4 2025. During this period, Niagen Bioscience maintained significant liquidity with $55.6 million in cash and no debt, ensuring financial flexibility for future endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.